Globus Medical (GMED)vsStryker Corporation (SYK)
GMED
Globus Medical
$87.35
+1.28%
HEALTHCARE · Cap: $11.67B
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 755% more annual revenue ($25.12B vs $2.94B). GMED leads profitability with a 18.3% profit margin vs 12.9%. SYK appears more attractively valued with a PEG of 1.60. GMED earns a higher WallStSmart Score of 74/100 (B).
GMED
Strong Buy74
out of 100
Grade: B
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.9%
Fair Value
$183.46
Current Price
$87.35
$96.11 discount
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 24.4%
Revenue surging 25.7% year-over-year
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
4.4% earnings growth
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GMED
The strongest argument for GMED centers on Altman Z-Score, Price/Book, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 24.4%. Revenue growth of 25.7% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio, EPS Growth.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
GMED profiles as a growth stock while SYK is a value play — different risk/reward profiles.
GMED carries more volatility with a beta of 1.07 — expect wider price swings.
GMED is growing revenue faster at 25.7% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
GMED scores higher overall (74/100 vs 65/100), backed by strong 18.3% margins and 25.7% revenue growth. SYK offers better value entry with a 16.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?